Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension
Open Access
- 1 September 2003
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (9) , 2588-2594
- https://doi.org/10.2337/diacare.26.9.2588
Abstract
OBJECTIVE—The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes. Insulin resistance may occur frequently in nondiabetic patients with hypertension. This study is the first to report the effect of pioglitazone on LDL subfractions in normolipidemic, nondiabetic patients with arterial hypertension. RESEARCH DESIGN AND METHODS—We performed a monocentric, double-blind, randomized, parallel-group comparison of 45 mg pioglitazone (n = 26) and a placebo (n = 28), each given once daily for 16 weeks. Fifty-four moderately hypertensive patients (LDL cholesterol, 2.8 ± 0.8 mmol/l; HDL cholesterol, 1.1 ± 0.3 mmol/l; triglycerides, 1.4 mmol/l (median; range 0.5–7.1) were studied at baseline and on treatment. RESULTS—At baseline, dense LDLs were elevated (apolipoprotein [apo]B in LDL-5 plus LDL-6 >250 mg/l) in 63% of all patients. Sixteen weeks of treatment with pioglitazone did not significantly change triglycerides, total, LDL, and HDL cholesterol. However, pioglitazone reduced dense LDLs by 22% (P = 0.024). The mean diameter of LDL particles increased from 19.83 ± 0.30 to 20.13 ± 0.33 nm (P < 0.001 vs. placebo), whereas the mean LDL density decreased from 1.0384 ± 0.0024 to 1.0371 ± 0.0024 kg/l (P = 0.005 vs. placebo). The effect of pioglitazone on LDL size and density was independent of fasting triglycerides and HDL cholesterol at baseline and of changes in fasting triglycerides and HDL cholesterol. CONCLUSIONS—The prevalence of atherogenic dense LDL in nondiabetic, hypertensive patients is similar to patients with type 2 diabetes. Pioglitazone significantly reduces dense LDL independent from fasting triglycerides and HDL cholesterol. The antiatherogenic potential of pioglitazone may thus be greater than that expected from its effects on triglycerides, LDL, and HDL cholesterol alone.Keywords
This publication has 49 references indexed in Scilit:
- Clinical pharmacokinetics of pioglitazoneExperimental and Clinical Endocrinology & Diabetes, 2000
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Insulin Resistance, Hyperinsulinemia, and Blood PressureHypertension, 1997
- Relation of LDL Size to the Insulin Resistance Syndrome and Coronary Heart Disease in American IndiansArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Pioglitazone (AD-4833) Ameliorates Insulin Resistance in Patients with NIDDMThe Tohoku Journal of Experimental Medicine, 1997
- Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycansAtherosclerosis, 1996
- Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.Journal of Clinical Investigation, 1995
- Predominance of Large LDL and Reduced HDL 2 Cholesterol in Normolipidemic Men With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Structure of human low-density lipoprotein subfractions determined by X-ray small-angle scatteringBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990